Allergic Bronchopulmonary Aspergillosis Prescreening Study

Inclusion Criteria: 1. Provide written informed consent before the performance of any study-specific procedures at the in-clinic visit. 2. Is a male or female ≥18 years old. 3. Has a BMI of ≥18.0 and \<40.0 kg/m2 at the in-clinic visit. 4. Meets the following criteria: 1. Has a diagnosis of asthma. 2. At least 1 exacerbation requiring a systemic glucocorticosteroid(s) or hospital admission in the last 10 months. 3. For patients on a biologic agent, at least one exacerbation requiring a systemic glucocorticosteroid(s) or hospital admission must have occurred at least 3 months after the initiation of the biologic agent. 5. Is willing and able to comply with all study procedures Exclusion Criteria: 1. Has used omalizumab (Xolair®) in the 11 months prior to screening or plans to use omalizumab during the study. 2. Has a current diagnosis of any chronic airway disease other than asthma, ABPA, or bronchiectasis believed to be related to ABPA, such as chronic obstructive pulmonary disease, pulmonary fibrosis, CF, or Churg-Strauss syndrome. 3. Currently requiring medications that are sensitive substrates for CYP3A4-mediated metabolism or medications that are contraindicated during and 2 weeks after treatment with oral formulations of itraconazole without the possibility of washout (See Appendix 4). 4. Smoking marijuana or tobacco, the use of e-cigarettes, vaping, or any other smoking is prohibited during the study. \-